Gaynelle Brown
Obstetrics & Gynecology · Albemarle, NCNPI 1760496897
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 34.0% of the total. Reporting peaked in 2022 at $1,442 and has fallen 69.2% since, to $444 in 2024. Among obstetrics & gynecology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$845
- Pfizer$283
- Exact Sciences$263
- Currax Pharmaceuticals LLC$262
- Daiichi Sankyo Inc.$207
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,50497%
- Education$1633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 110 | $1,585 |
| AbbVie(2 entities) | 58 | $845 |
| Pfizer | 15 | $283 |
| Exact Sciences | 13 | $263 |
| Currax Pharmaceuticals LLC | 20 | $262 |
| Daiichi Sankyo Inc. | 8 | $207 |
| Astellas Pharma US Inc | 4 | $198 |
| Mylan Pharmaceuticals Inc. | 8 | $148 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $125 |
| Lilly USA, LLC | 7 | $122 |
| Exeltis, USA Inc. | 6 | $101 |
| Avion Pharmaceuticals | 6 | $100 |
| Therapeuticsmd, Inc. | 5 | $85 |
| Organon | 7 | $79 |
| Shield Therapeutics Inc | 3 | $54 |
| Mission Pharmacal Company | 3 | $46 |
| Evofem Biosciences, Inc. | 2 | $39 |
| Myovant Sciences Inc. | 2 | $34 |
| Vivus LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $15 |
| Merck | 1 | $15 |
| Bayer | 1 | $13 |
How this compares
$4,667 in reported general payments places this provider in the 90th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
See all obstetrics & gynecology providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Raloxifene Hcl | 12 | $99 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Albemarle
- Jerry MatkinsCharlotte$481K
- Laura McKainWilmington$475K
- Leslie Hansen-LindnerCharlotte$372K
- Robin MatthewsClyde$217K
- Haywood BrownDurham$165K
- Jack IngeRaleigh$157K
- Geeta SwamyDurham$142K
- Karie LafleurAsheville$135K
- Ty RobinsonHigh Point$114K
- Shan BiscetteCharlotte$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.